Abstract 4300: Selective GFP labeling of cancer with a telomerase-specific adenovirus (OBP-401) to report future recurrence after resection

Abstract We have previously developed a telomerase-specific replicating adenovirus expressing GFP (OBP-401). Intraperitoneal (i.p.) injection of OBP-401 specifically labeled peritoneal tumors with GFP enabling real-time surgical navigation. However, technical difficulty of removing microscopic tumors still remains, which makes it difficult to eradicate disease completely, even after so-called complete resection. In this study we report an additional advantage of OBP-401. Weeks after surgical navigation with OBP-401, recurrent tumor nodules were observed with GFP imaging, indicating that OBP-401 treatment for peritoneal disseminated disease enabled detection of its subsequent recurrence after surgical navigation. Thus tumor labeling with a genetic reporter has important advantages over antibody and other non-genetic labeling since reminant disease remains labeled and can be further resected. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4300. doi:10.1158/1538-7445.AM2011-4300